News FDA experts back Novo Nordisk's key diabetes drug Novo hopes for blockbuster sales from semaglutide
News Automatic artificial pancreas shows promise in trial Experimental device requires no user input at all.
News J&J hopes FDA cardio label will limit Invokana damage Diabetes drug has been hit by amputation warning on label.
News No cardio protection indication for Novo's semaglutide - yet Danish pharma plans outcome trial to confirm benefits in SUSTAIN 6
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
